Business Wire

Inversago Pharma Initiates Clinical Trials, with a Phase 1 study of INV-101, the Company’s Lead Peripheral CB1 Blocker

Share

Inversago Pharma Inc. (“the Company” or “Inversago”), the peripheral CB1 blockade company, today announced it has initiated a Phase 1 clinical trial of INV-101, the Company’s peripherally-acting CB1 blocker, which is being developed for the treatment of Prader-Willi syndrome (PWS) and non-alcoholic steatohepatitis (NASH).

The trial will evaluate the safety, tolerability and pharmacokinetics of INV-101. Recruitment is ongoing and will enroll healthy participants in Canada, from 18 to 55 years old. Subjects will initially be randomized to receive a single dose of placebo or one of 5 dose levels of INV-101.

“With the launch of this first-in-human trial, Inversago is now a clinical-stage company, and confirms its lead in the comeback of small molecule peripheral CB1 blockers”, said François Ravenelle, PhD, CEO and founder of Inversago Pharma.

“Dosing of our first patient with INV-101 represents an important milestone to accomplish the Company’s vision: offering a potentially meaningful therapeutic option to underserved patient populations, like in PWS and NASH" said Carlo Incerti, M.D., Chairman of the Board of Inversago. "This study is the first step in the clinical development of our peripherally-acting CB1 blockers, and we expect it to provide important information about its safety and pharmacokinetics profile", concluded Dr. Incerti.

The Company’s second program, INV-202, is presently in IND-enabling preclinical studies, while other programs are in earlier stages of development. With its current pipeline, Inversago is well positioned to fully exploit peripheral CB1 blockade for a wide range of underserved metabolic indications with differentiated products.

About INV-101

INV-101 is a first-in-class, small molecule CB1 inverse agonist / antagonist being developed by Inversago for the treatment of PWS and NASH. It is specifically designed to interact with peripheral CB1 receptors located in the gastro-intestinal tract, liver, pancreas, adipose tissues, muscles, lungs and other organs, thus aiming at a safe and effective therapeutic approach without the known liabilities of centrally-acting CB1 blockers. The peripheral CB1 blockade is a well-documented pathway, linked to many clinically meaningful metabolic benefits.

About Inversago Pharma

Inversago Pharma is a clinical-stage, biotech company specialized in the development of new therapies focusing on CB1 blockade, based on first-in-class, peripherally-acting CB1 inverse agonists. The Company aims to provide new treatment options that improve the lives of patients affected by metabolic conditions such as Prader-Willi Syndrome (PWS), non-alcoholic steatohepatitis (NASH), type 1 diabetes (T1D) and diabetic nephropathy. For more information, visit inversago.com.

Picture of our CEO and company logotype available for download at: inversago.com/en/media/

Contact information

François Ravenelle, PhD
CEO & Founder
Inversago Pharma inc.
info@inversago.com

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Five Highlights at the 26 th Yiwu Fair to Attract 50,000 Global Merchants22.10.2020 16:25:00 CESTPress release

The 26th China Yiwu International Commodities (Standards) Fair ("Yiwu Fair") was opened on October 21 at Yiwu International Expo Center. The event, which will last till October 25, is expected to attract over 50,000 businessmen worldwide with these five highlights that can’t be missed. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201022005798/en/ Highlight 1: Encouraging online and offline trade Due to the COVID-19 pandemic, exporters are facing great challenges this year. Therefore, Yiwu Fair 2020 invited more foreign business organizations and their representative offices in China. Around 10 delegations with 1,600 foreign businessmen in China are expected to attend. And online trade matchmaking meetings targeting Malaysia, the United Kingdom, Chile, etc. will allow exhibitors to connect with oversea traders online while meeting on-site foreign traders. Meanwhile, matchmaking meetings will also be held to help exhibitors

Hilton Effect Foundation Reveals 2020 Grants and Achieves $1 Million in Global COVID-19 Community Response Efforts22.10.2020 16:00:00 CESTPress release

The Hilton Effect Foundation announced today its 2020 Hilton Effect grantees, which include community-based organizations playing a direct role in COVID-19 pandemic recovery efforts. Through these grants and donations already made by the Foundation, which serves as Hilton’s primary philanthropic arm, the Foundation has now awarded more than $1 million dollars in COVID-19 community response efforts. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201022005724/en/ Hilton Effect Foundation reveals 2020 grants and achieves $1 million in global COVID-19 community response efforts. (Graphic: Hilton Effect Foundation) “A core part of the Hilton Effect Foundation’s work is to support our communities around the world through both good times and bad,” said Kate Mikesell, president, Hilton Effect Foundation. “From the very start of the pandemic, we have been listening to community leaders about the direct and indirect challenges they ar

Smiths Detection Inc. receives a $90.8M IDIQ contract to manufacture Joint Chemical Agent Detector Adapter for US Department of Defense22.10.2020 16:00:00 CESTPress release

Smiths Detection Inc. (SDI), a global leader in threat detection and security screening technologies, announced it will initiate manufacturing of the Solid Liquid Adapter (SLA) following an indefinite delivery/indefinite quantity (IDIQ) award, worth potentially $90.8M over a maximum nine (9) year ordering period, with the US Department of Defense (DoD). The SLA adds new and expanded detection and identification capabilities to Joint Chemical Agent Detectors (JCAD), one of the DoD’s largest chemical detection programs in history. JCAD fitted with an SLA (JCAD SLA) gives the SLA operator the ability to both test for illicit drugs, including opioids such as fentanyl, and detect explosive compounds – without compromising the conventional chemical warfare agent detection capability of the JCAD. Speaking about the newly developed technology, Smiths Detection Inc. President, Shan Hood, said, “The SLA leverages existing technology, extending both capabilities and the life-cycle of widely deplo

Andersen Global Adds Chancery Chambers to Caribbean Platform22.10.2020 15:30:00 CESTPress release

Continuing to add breadth to the organization’s coverage in the eastern Caribbean region, Andersen Global enters into a Collaboration Agreement with legal firm Chancery Chambers in Barbados. Founded by Partner Sir Trevor Carmichael, Chancery Chambers is ranked Band 1 by Chambers and Partners and has substantial public and private sector experience at the national and international level. The firm’s full-service capabilities include national and international arbitration, corporate and commercial, employment law, banking and finance, aviation law, environmental law, intellectual property, insurance, M&A and real estate, specializing in tax advisory, corporate advisory and litigation. “We remain dedicated to being a benchmark organization for quality and best-in-class client solutions, and we believe the best way to accomplish this is by investing in our people and in our firm,” Sir Trevor said. “We are focused on the future and laying the groundwork for the next generation. Our collabor

Moody’s Retires Green Bond Assessment Product in Light of Market-Leading Second - Party Opinion Service Available from its Affiliate Vigeo Eiris22.10.2020 15:18:00 CESTPress release

Moody’s announced today that it has retired its Green Bond Assessment (GBA) product in light of the market-leading Second-Party Opinion (SPO) Service for sustainable bonds provided by its affiliate Vigeo Eiris (VE). This move follows the recently announced formation of the Moody’s ESG Solutions Group and last year’s expansion of Moody’s ESG capabilities with investments in VE, a global pioneer in ESG assessments, data, tools and sustainable finance; and Four Twenty Seven, a leader in climate risk analysis. VE offers a range of leading sustainable finance solutions, including a recently-enhanced SPO service for green, social, sustainability, and transition bonds as well as issuer sustainability ratings that provide an in-depth and forward-looking evaluation on a company’s sustainability credentials. In view of VE’s market-leading SPO product, Moody’s Investors Service (MIS) has retired the GBA product and has withdrawn all outstanding GBAs today. “The sustainable bond market has been on

IAVI, Merck, and Serum Institute of India Join Forces to Develop Monoclonal Antibodies for COVID-19 and Ensure Prompt and Equitable Global Access22.10.2020 15:00:00 CESTPress release

Today, IAVI, a nonprofit scientific research organization dedicated to addressing urgent, unmet global health challenges, and Serum Institute of India Pvt. Ltd., a leading manufacturer of vaccines and biologics, announced an agreement with Merck, a leading science and technology company, to develop SARS-CoV-2 neutralizing monoclonal antibodies (mAbs) co-invented by IAVI and Scripps Research as innovative interventions to address the COVID-19 pandemic. The agreement builds on the advanced antibody discovery and optimization expertise of IAVI and Scripps Research, gained from years of experience in HIV broadly neutralizing antibody research and development, and on Merck’s and Serum Institute’s significant capabilities in design and scale up of accelerated manufacturing processes for mAb production. The global development plan is being led by the three organizations in partnership. The two companies have broad networks across complementary geographic areas that will be crucial to reach gi